[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574521":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":45,"id":49,"slug":20,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CHT102 infusion","EXPERIMENTAL","CHT102 will be dosing by arterial infusion.",[13],"Drug: CHT102",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","CHT102","CHT 102 : MSLN UCAR-T.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Jihui Hao, Ph.D","CONTACT","+86-02223340123","haojihui@tjmuch.com",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Tianjin Medical University Cancer Institute & Hospital","RECRUITING","Tianjin","China",{"type":34,"coordinates":35},"Point",[36,37],117.17667,39.14222,{"lat":37,"lon":36},[40,41],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":23,"role":42,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[46],{"name":47,"class":48},"Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.","INDUSTRY","100574521",false,"NCT06760364","A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer","A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer","CHAMPION","Inclusion Criteria:\n\n1. Ability to understand and sign a written informed consent documen；\n2. At the date of signing ICF, 18 \\~70 years old, male or female；\n3. Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；\n4. Positive mesothelin expression;\n5. At least one measurable lesion at baseline per RECIST version 1.1；\n6. The expected survival time is more than 12 weeks;\n7. ECOG 0-1 points;\n8. Adequate organ functions.","ALL","18 Years","70 Years",{"count":60,"type":61},21,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer",[67],"Advanced Pancreatic Cancers",[69,70,71,72],"Allogeneic CAR-T","Safety","Efficacy","PK","2025-04-07",{"date":75,"type":76},"2025-04-10","ACTUAL",{"date":78,"type":76},"2024-12-25",{"date":80,"type":61},"2039-12-24",{"name":5,"class":6},1]